A first-in-human phase 1 clinical trial of CpG STAT3siRNA gene therapy in B-cell non-Hodgkin lymphoma patients
Latest Information Update: 27 May 2021
At a glance
- Drugs DUET 01 (Primary)
- Indications B-cell lymphoma; Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
Most Recent Events
- 24 May 2021 According to a Scopus BioPharma media release, the company has received the approval of an investigational new drug application (IND) by the United States Food and Drug Administration (FDA).
- 26 Apr 2021 According to a Scopus BioPharma media release, the company announced the submission of an investigational new drug application to the United States Food and Drug Administration for its immuno-oncology RNA therapy for the treatment of multiple cancers.
- 19 Jan 2021 According to a Scopus BioPharma media release, clinical lot manufacturing has been completed fulfilling the requirements of this study and this will enable finalization of the investigational new drug ("IND") package for submission to the United States Food and Drug Administration.